Transurethral Balloon Dilatation of the Prostate and Transurethral Plasmakinetic Resection of the Prostate in the Treatment of Prostatic Hyperplasia. | [Pakistan Journal of Medical Sciences • 2018]

Author(s):

1. Yanhua Chang: Yanhua Chang, Dept. of Urology Surgery, Binzhou People's Hospital, Shandong, 256610, China

2. Jingyi Chang: Yanhua Chang, Dept. of Urology Surgery, Binzhou People's Hospital, Shandong, 256610, China

3. Hui Wang: Yanhua Chang, Dept. of Urology Surgery, Binzhou People's Hospital, Shandong, 256610, China

Abstract:

Background & Objective: With the aggravation of global aging, benign prostate hyperplasia tends to have a higher incidence and has been the most common disease in urinary surgery. It is usually treated by surgery. Our objective was to select an effective treatment scheme, the clinical efficacy and relevant indicators of transurethral balloon dilatation of the prostate (TUDP) and transurethral plasmakinetic resection of the prostate (PKRP) in the treatment of benign prostate hyperplasia were emphatically compared. Methods: Ninety-eight patients with benign prostate hyperplasia who were admitted to the hospital of between May 2014 and July 2016 were selected and divided into a TUDP group (n=49) and PKRP (n=49) using random number table. The intraoperative blood loss, duration of surgery, international prostate symptom score (IPSS), quality of life (QOL), post-void residual urine (PVR) and complications of the two groups were observed. Results: The results demonstrated that the postoperative blood loss and duration of surgery of the patients in the PKRP group were significantly higher than those of the TUDP group (P<0.05); the IPSS, QOL and PVR of the patients in the two groups after surgery were much lower than those before surgery (P<0.05); the IPSS, QOL and PVR of the patients in the PKRP group were significantly lower than those in the TUDP group after surgery (P<0.05). The incidence of postoperative complications of the PKRP group was 38.8%, which was apparently higher than 14.3% in the TUDP group (P<0.05). Conclusion: PKRP has better efficacy than TUDP in treating benign prostatic hyperplasia, but QOL was poor and there are many complications. Proper surgical procedure should be selected according to the specific disease condition of patients.

Page(s): 736-739

DOI: DOI not available

Published: Journal: Pakistan Journal of Medical Sciences, Volume: 34, Issue: 3, Year: 2018

Keywords:

Keywords are not available for this article.

References:

[1] LiuYB,LiJQ, 2014.Observation of transurethral plasmsakinetic resection for 76 cases of benign prostatic hyperplasia,Chin Foreign Med Res 130 -131

[2] LiX,PanJH,LiuQG,HeP,SongSJ,JiangT, 2013.Selective transurethral resection of the prostate combined with transurethral incision of the bladder neck for bladder outlet obstruction in patients with small volume benign prostate hyperplasia (BPH): A prospective randomized study,PloS One 0063227 -

[3] LukacsB,LoeflerJ,BruyereF,BlanchetP,GeletA,ColobyP, 2012.Photoselective vaporization of the prostate with Green Light 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial,Euro Urol 01 1165 -1173

[4] MillerDC,SaigalCS,LitwinMS, 2008.The demographic burden of urologic diseases in America,Urol Clin North Am 08 11 -27

[5] LukkarinenO,LehtonenT,TaljaM,LundstedtS,TiitinenJ,TaariK., 1999.Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study,Ann Chir Gynaecol 88 299 -303

[6] TubaroA,CarterS,HindA,VicentiniC,Miano L, 2001.A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia,J Urol 5347 66102 -2

[7] ZhouX,ChenYH,CaiY., 2005.Common reasons and prevention of complications after transurethral resection of prostate for aged patients,J Pract Med 21 1072 -1073

[8] Huang W, Guo Y, Xiao G, Qin X. Treatment of benign prostatic hyperplasia using transurethral split of the prostate with a columnar balloon catheter. J Endourol. 2015;29(3):344-350. doi: 10.1089/end.2014.0207.

[9] LukkarinenO,LehtonenT,TaljaM,LundstedtS,TiitinenJ,TaariK., 1999.Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study,Ann Chir Gynaecol 88 299 -303

[10] Rocco B, Albo G, Ferreira R C, Spinelli M, Cozzi G, Dell’orto P, Patel V, Patel F. Recent advances in the surgical treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3(6):263-272. doi: 10.1177/1756287211426301.

[11] Wu Y, Davidian MH, Desimone EM. Guidelines for the treatment of benign prostatic hyperplasia. US Pharm. 2016;41(8):36-40.

[12] Biester K, Skipka G, Jahn R, Buchberger B, Rohde V, Lange S. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence(non-inferiority). BJU Int. 2012;109(5):722-730. doi: 10.1111/j.1464-410X.2011.10512.x.

[13] Li X, Pan JH, Liu QG, He P, Song SJ, Jiang T, et al. Selective transurethral resection of the prostate combined with transurethral incision of the bladder neck for bladder outlet obstruction in patients with small volume benign prostate hyperplasia (BPH): A prospective randomized study. PloS One. 2013;8(5):e63227. doi: 10.1371/journal.pone.0063227.

Citations

Downloads

Views